¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Poisoning by agents primarily affecting the cardiovascular system"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • genital system
    »ý½Ä°èÅë, »ý½Ä°è, »ý½Ä±â°è
  • genitourinary system
    ºñ´¢»ý½Ä°èÅë, ºñ´¢»ý½Ä°è
  • Haversian system
    ÇϹö½º°è
  • health care delivery system
    ÀÇ·áÀü´Þü°è
  • hypophyseal portal system
    ³úÇϼöü¹®¸Æ°è
  • health care system
    º¸°ÇÀÇ·áü°è
  • health information system
    º¸°ÇÁ¤º¸Ã¼°è
  • hematopoietic system
    Ç÷±¸Çü¼º°èÅë, Á¶Ç÷°è
  • hospital information system
    º´¿øÁ¤º¸Ã¼°è
  • immobilization system
    °íÁ¤¹æ½Ä
  • immune system
    ¸é¿ªÃ¼°è
  • impulse conducting system
    ½ÉÀåÈïºÐÀüµµ°èÅë
  • information system
    Á¤º¸Ã¼°è
  • integumentary system
    ÇǺΰèÅë, ¿ÜÇǰè
  • International System of Units
    ±¹Á¦´ÜÀ§°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • hematopoietic system
    Á¶Ç÷±â°ü°èÅë
  • hospital discharge abstract system
    Åð¿ø±â·Ï¿ä¾àÁ¦µµ
  • hospital information system
    º´¿øÁ¤º¸Ã¼°è
  • immobilization system
    °íÁ¤¹æ½Ä
  • immune system
    ¸é¿ªÃ¼°è
  • impulse conducting system
    ½ÉÀåÈïºÐÀüµµ°èÅë
  • information system
    Á¤º¸Ã¼°è
  • infusion-aspiration system
    ÁÖÀÔÈíÀÔÀåÄ¡
  • integumentary system
    ÇǺΰèÅë
  • interofective system
    ³»ºÎȯ°æÁ¶Àý°è
  • interrenal system
    ºÎ½Å°ÑÁú°è
  • intrarenal collecting system
    ÄáÆÏ¼ÓÁý´¢°è
  • irrigation-aspiration system
    °ü·ùÈíÀÔÀåÄ¡
  • limbic system
    °¡ÀåÀÚ¸®°èÅë, º¯¿¬°è
  • local health system
    Áö¹æÀÇ·áü°è
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Rh blood group system
    Rh Ç÷¾×Çü±º
  • Rh system
    RhÇ÷¾×Çü°è
  • Rosenfield system
    ·ÎÁ¨Çʵå°è
  • SI unit => International System of Unit
    ±¹Á¦±Ô°Ý´ÜÀ§
  • T system
    T°èÅë.
  • V-Tech urinalysis system
    V-Tech ¿äºÐ¼®Ã¼°è
  • Wiener system
    À§³Êü°è
  • Wilkerson point system
    ÀªÄ¿½¼Á¡¼öü°è
  • achromatic system
    ¹«»ö°è.
  • acid-base buffer system
    »ê¿°±â¿ÏÃæ°è
  • adrenal medulla,tumor of chemoreceptor system
    È­Çмö¿ëü°è Á¾¾ç(ûùùÊáôé»ô÷ͧ ðþåË)
  • adrenal system
    ºÎ½Å°è(Üùãìͧ).
  • aerospace life support system
    (Ç×°ø)¿ìÁÖ¿ë »ý¸íÀ¯Áö½Ã½ºÅÛ.
  • affectional system
    Á¤µ¿Ã¼°è
  • alimentary system(tract)
    ¼ÒÈ­±â°è(á¼ûùÐïͧ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • heavy metal poisoning
    Á߱ݼÓÁßµ¶(¡­ñéÔ¸).
  • industrial poisoning
    °ø¾÷Áßµ¶(Ë­ËâÌ¡ËÄ).
  • insecticide poisoning
    »ìÃæÁ¦Áßµ¶
  • insecticide poisoning
    »ìÃæÁ¦ Áßµ¶(߯õùð¥ ñéÔ¸)
  • iodine poisoning
    ¿äµåÁßµ¶(¡­ñéÔ¸).
  • iron poisoning
    öÁßµ¶
  • isopropyl alcohol poisoning
    À̼ÒÇÁ·ÎÇʾËÄÝÁßµ¶Áõ
  • jengkol poisoning
    Á­ÄÝÁßµ¶(¡­ñéÔ¸).
  • kerosene poisoning
    µîÀ¯ Áßµ¶(Ôóêú ñéÔ¸)
  • lead poisoning
    ¿¬Áßµ¶(æçñéÔ¸), ³³Áßµ¶.
  • lead poisoning
    ³³ Áßµ¶(Ò£ ñéÔ¸)
  • loco poisoning
    ·ÎÄÚÁßµ¶Áõ.
  • lye poisoning
    ¾çÀí¹°Áßµ¶(¡­ñéÔ¸).
  • lye poisoning
    ¾çÀí¹°Áßµ¶(ÊÙÌ¡ËÄ).
  • meat poisoning
    °í±âÁßµ¶(¡­ñéÔ¸).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
CCI Cardiovascular Credentialing International; cholesterol crystallization inhibitor; chronic coronary ...
CCS Canadian Cardiovascular Society; casualty clearing station; cell cycle specific; cholecystosonograph...
CCVM congenital cardiovascular malformation
CD cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise...
CICU cardiac intensive care unit; cardiovascular inpatient care unit; coronary intensive care unit
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
AMS AUTO-MICROBIC-SYSTEM
ARMS Amplification Refractory Mutation System
AIMS Anaesthesia Information Management System
ARIS Apoenzyme Reactivation Immunoassay System
ATPS Aqueous two-phase system
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • drug delivery system
    ¾à¹° Åõ¿©±â, ¾à¹° Åõ¿© üÁ¦, ¾à¹° Àü´Þ ü°è
  • dual foil system
    ÀÌÁß ¹Ú¸· ±¸Á¶
  • ductal system
    µµ°ü°è
  • dynamic system
    µ¿Àû °èÅë
  • ectopic system
    »ýŰè
    ¾î¶² Áö¿ªÀÇ »ý¹° °øµ¿Ã¼¿Í À̰ÍÀ» À¯ÁöÇϰí ÀÖ´Â ¹«±âÀû ȯ°æÀÌ Á¾ÇÕµÈ ¹°Áú°è ¶Ç´Â ±â´É°è. »ýŰè¶õ ¿µ±¹ÀÇ A.G. ÅĽ½¸®¿¡ ÀÇÇÏ¿© 1935³â Á¦Ã¢µÈ ¿ë¾î·Î, ÀÚ¿¬ÀÇ ÀÖ´Â ±×´ë·ÎÀÇ »óŸ¦ ÀνÄÇϱâ À§Çؼ­´Â ÀÌ°Íµé »óÈ£°£ÀÇ °ü°è¸¦ Áö´Ñ »ý¹°°ú ¹«±âÀû ȯ°æÀ» Çϳª·Î ÅëÇÕÇØ¾ß ÇÑ´Ù´Â °ÍÀÌ ÅĽ½¸®°¡ Á¦Ã¢ÇÑ °³³äÀÌ´Ù. Áö±¸ »ýŰè´Â ±× ³ÐÀÌ¿¡¼­´Â »ý¹°±Ç°ú ÀÏÄ¡ÇÑ´Ù. ¹«±âÀû ȯ°æÀÇ Æ¯Â¡¿¡ ÀǰÅÇÏ¿© ÇØ¾ç »ýŰè, È£¼Ò »ýŰè, ±ØÁö »ýŰè, »ç¸· »ýÅÂ°è µîÀ¸·Î ±¸º°Çϰí, ¶Ç ±º¶ôÀÇ »ó°ü¿¡ µû¶ó¼­ »ï¸² »ýŰè, ÃÊÁö »ýÅÂ°è µîÀ¸·Î ±¸ºÐÇϱ⵵ ÇÑ´Ù. ¶ÇÇÑ, °æÁö »ýŰè, µµ½Ã »ýŰè¿Í °°Àº °Íµµ »ý°¢ÇÒ ¼ö ÀÖ´Ù. »ýŰè Áß¿¡¼­ »ý¹°Ã¼´Â ±â´ÉÀûÀ¸·Î »ý»êÀÚ
  • endocrine system
    ³»ºÐºñ°è
    ÀÎüÀÇ Á¶Àý ±â´ÉÀ¸·Î ¼¼Æ÷°£ÀÇ ´ëÈ­¸¦ È­ÇÐ ¹°ÁúÀΠȣ¸£¸óÀ» ÅëÇØ¼­ È­ÇÐÀûÀÎ ½ÅÈ£¸¦ ÀÌ¿ëÇÏ¿© Ç¥Àû ¼¼Æ÷µé¿¡ ÀÛ¿ëÇÑ´Ù. ÈçÇÑ ³»ºÐºñ°è ÀÌ»óÀº ºñÁ¤»óÀûÀÎ ¼ºÀå, ¿¡³ÊÁö ¼öÁØ º¯È­ ¿Âµµ º¯È­¿¡ÀÇ ºÎÀûÀÀ ¹× ¼³¸íµÇÁö ¾Ê´Â üÁß º¯È­·Î ³ªÅ¸³­´Ù. ´Ù´¢, °úµµÇÑ °¥Áõ, üÁß °¨¼Ò¸¦ µ¿¹ÝÇÑ ½Ä¿å °ú´Ù´Â ´ç´¢º´ÀÇ Æ¯Â¡ÀÌ´Ù. ½Ã·Â º¯È­, ½ÅÀå ±â´ÉÀå¾Ö, »çÁöÀÇ Ç÷¾× ¼øÈ¯ °¨¼Ò´Â Àå±â°£ÀÇ ´ç´¢·Î ÀÎÇÑ ÁøÇàµÈ Ç÷°ü °æÈ­ÀÇ Áõ»óÀÌ´Ù.
  • endogenous analgesic peptide system
    ³»¿ø¼º ÁøÅ뼺 ÆéƼµå°è
  • epidermal system
    Ç¥Çǰè
  • excretory system
    ¹è¼³°è
  • extrapyrarnidal system
    Ãßü¿Ü·Î°è
  • fiber optic delivery system
    ±¤ ¼¶À¯ Àü´Þ°è
  • fingerprint system
    Áö¹®°è
  • fusimotor system
    ¹æÃß ¿îµ¿°è
  • human system
    ÀÎü°è
  • hypophyseal portal system
    ³úÇϼöü ¹®¸Æ °èÅë, Çϼöü ¹®¸Æ°è
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
anti-asthmatic agents Drugs that are used to treat asthma.
(12 Dec 1998)
anticarcinogenic agents Agents that reduce the frequency or rate of spontaneous or induced tumours independently of the mechanism involved. They differ from antineoplastic agent in that they prevent neoplasms from forming. The anticarcinogenic substances can be divided into three categories. The first consists of compounds that prevent the formation of carcinogens from precursor substances. The second group consists of "blocking agents" which inhibit carcinogenesis by preventing carcinogenic agents from reaching or reacting with critical target sites in the tissues. The third group is the "suppressor agents" which act by suppression of expression of neoplasia in cells previously exposed to carcinogens that would otherwise cause neoplasms.
(12 Dec 1998)
anticestodal agents Agents used to treat tapeworm infestations in man or animals.
(12 Dec 1998)
anticholesteraemic agents Substances that promote a reduction of blood cholesterol levels.
(12 Dec 1998)
anti-coagulant agents Medications, like heparin, used as blood-thinners to prevent blood clots and to maintain open blood vesssels.
(12 Dec 1998)
antidepressive agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several monoamine oxidase inhibitors are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (antidepressive agents, tricyclic) also appear to act through brain catecholamine systems. A third group (antidepressive agents, second-generation) is a diverse group of drugs including some that act specifically on serotonergic systems.
(12 Dec 1998)
antidepressive agents, second-generation A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
(12 Dec 1998)
antidepressive agents, tricyclic Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.
(12 Dec 1998)
anti-dyskinesia agents Drugs used in the treatment of movement disorders. most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of parkinson disease (antiparkinson agents) and those for the tardive dyskinesias.
(12 Dec 1998)
antifoaming agents Agents used to prevent the formation of foam or to treat flatulence or bloat.
(12 Dec 1998)
antifungal agents Agents destructive to fungi, suppressing their growth or reproduction, and effective against fungal infections. They differ from fungicides, industrial in that antifungal agents are restricted to action against fungi present in human or animal tissues.
(12 Dec 1998)
anti-HIV agents Agents used to treat aids and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with aids.
(12 Dec 1998)
antihypertensive agents Drugs used in the treatment of acute or chronic hypertension regardless of pharmacological mechanism. Among the antihypertensive agents are diuretics (especially diuretics, thiazide), adrenergic beta-antagonists, adrenergic alpha-antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, ganglionic blockers, and vasodilator agents.
(12 Dec 1998)
anti-infective agents, local Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from disinfectants, which are used on inanimate objects.
(12 Dec 1998)
anti-infective agents, quinolone A group of synthetic antimicrobial agents which usually contain a 4-quinolinone ring structure. A few compounds belonging to this group have related nitrogen heterocyclic ring structures such as naphthyridine or phthalazine groups. All compounds in this group are substituted with an oxo group at the 4-position. The second-generation quinolones are also substituted with a 1-piperazinyl group at the 7-position and a fluorine moiety at the 6-position. The quinolones inhibit the a subunit of DNA gyrase and thus interfere with the ability of the enzyme to repair bacterial DNA breaks during replication. The compounds have a broad spectrum of activity against a variety of aerobic bacteria.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • mercantile system
    Áß»óÁÖÀÇ
  • merit system
    (ÀÓ¿ë,½ÂÁøÀÇ) ½ÇÀû(¼ºÀû)Á¦;½Ç·Â º»À§ Á¦µµ
  • metric system
    ¹ÌÅ͹ý
  • metric system
    ¹ÌÅ͹ý(µµ·®Çü º¾¿¡¼­ ´ÜÀ§¸¦ meter,liter,gramÀ¸·Î ÇÔ)
  • mountain system
    »ê°è
  • natural system
    ÀÚ¿¬ºÐ·ù(natural classification)
  • nervous system
    ½Å°æ°èÅë
  • numbering system
    ¼ýÀÚ¸¦ »ç¿ëÇÏ¿© Ŭ·¹À̸¦ ³ªÅ¸³»´Â ¹æ½Ä(°¢ ¼±¼öÀÇ À§Ä¡,¼±¼ö°£ÀÇ Áö¿ª¿¡ ¹øÈ£¸¦ ºÙÀÓ)
  • oneline real time system
    Á÷°á ½Ç½Ã°£ ó¸® ¹æ½Ä
  • parasympathetic nervous system
    ºÎ±³°¨ ½Å°æ°è
  • periodic system
    ÁÖ±â°è;ÁÖ±âÀ²¿¡ µû¸¥ ¿ø¼Ò ü°è
  • peripheral nervous system
    ¸»ÃÊ ½Å°æ°è
  • point system
    Æ÷ÀÎÆ®½Ä;¸ÍÀοëÀÇ Á¡ÀÚ ¹æ½Ä;ÇÐÁ¡Á¦;¿îÀü À§¹ÝÀÇ Á¡¼öÁ¦
  • premium system
    »ó¿© Á¦µµ(½Ã°£±ÞÀ» Á¤ÇÏ°í ¼ÒÁ¤ ½Ã°£º¸´Ù »¡¸® µÇ¸é ÇÒÁõ ±Þ¿©¸¦ ÁÜ)
  • private-wire system
    »ç¼³ ÀüÈ­(ÅÚ·º½º) ȸ¼±¸Á
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á